Onyvax Company
Onyvax develops cancer therapies that harness the selective power of the immune system to seek out and destroy tumor cells.
Last Funding Type:
Series C
Last Funding Date:
2006-05-08
Funding Status:
Late Stage Venture
Headquarters:
Bradford, Somerset, United Kingdom
Industry:
Whole-Cell Antigens
Total Funding:
29810445
Investors Number:
5
Employee Number:
11-50
Founded Date:
1997-01-01